Evidence map›Paper›PMID 24714746›Full record

ArticleBritish journal of cancer2014

High CXC chemokine receptor 4 expression is an adverse prognostic factor in patients with clear-cell renal cell carcinoma.

H An, L Xu, Y Zhu, T Lv, W Liu, Y Liu, H Liu, L Chen, J Xu, Z Lin

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in British journal of cancer, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 3 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 3 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Article
  5. Article
  6. Review
  7. Article
  8. Review
  9. Article
  10. Interleukin-9 promotes cell survival and drug resistance in diffuse large B-cell lymphoma.Journal of experimental & clinical cancer research : CR · 2016
    Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

H AnDepartment of Urology, Zhongshan Hospital, Shanghai Medical College of Fudan University, Shanghai 200032, China.
L XuDepartment of Urology, Zhongshan Hospital, Shanghai Medical College of Fudan University, Shanghai 200032, China.
Y ZhuDepartment of Urology, Ninth People's Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai 200011, China.
T LvDepartment of Urology, Zhongshan Hospital, Shanghai Medical College of Fudan University, Shanghai 200032, China.
W LiuDepartment of Biochemistry and Molecular Biology, Key Laboratory of Glycoconjugate Research, MOH, School of Basic Medical Sciences, Shanghai Medical College of Fudan University, Shanghai 200032, China.
Y LiuDepartment of Biochemistry and Molecular Biology, Key Laboratory of Glycoconjugate Research, MOH, School of Basic Medical Sciences, Shanghai Medical College of Fudan University, Shanghai 200032, China.
H LiuDepartment of Biochemistry and Molecular Biology, Key Laboratory of Glycoconjugate Research, MOH, School of Basic Medical Sciences, Shanghai Medical College of Fudan University, Shanghai 200032, China.
L ChenDepartment of Pathology, Children's Hospital, Shanghai Medical College of Fudan University, Shanghai 201102, China.
J XuDepartment of Biochemistry and Molecular Biology, Key Laboratory of Glycoconjugate Research, MOH, School of Basic Medical Sciences, Shanghai Medical College of Fudan University, Shanghai 200032, China.
Z LinDepartment of Urology, Zhongshan Hospital, Shanghai Medical College of Fudan University, Shanghai 200032, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAberrant CXC chemokine receptor 4 (CXCR4) expressions in malignant tissues have been reported; however, its role in kidney cancer prognosis remains unknown. The aim of this study was to determine the prognostic value of CXCR4 expression in patients with clear-cell renal cell carcinoma (ccRCC).

methodsThe study included 225 patients with ccRCC. The cohort was split into a training set (n=125) and a validation set (n=100). CXC chemokine receptor 4 expression was analysed by immunohistochemical staining and its correlations with clinicopathologic features and prognosis were evaluated.

resultsCXCR4-staining intensity increased gradually accompanied with disease progression from TNM stages I to IV in 225 patients with ccRCC. Moreover, high CXCR4 expression indicated reduced overall survival (OS) in the training (P<0.001) and validation (P<0.001) sets, especially for patients with early-stage (TNM stage I+II) diseases. Furthermore, CXCR4 expression was identified as an independent prognostic factor for OS, and combining TNM stage with CXCR4 expression showed a better prognostic value for OS in both sets.

conclusionsHigh CXCR4 expression, an independent adverse prognostic factor, could be combined with TNM stage to generate a predictive nomogram for clinical outcome in patients with ccRCC.

Indexed as

AgedBiomarkers, TumorCarcinoma, Renal CellCohort StudiesFemaleHumansKidney NeoplasmsMaleMiddle AgedNeoplasm StagingPrognosisReceptors, CXCR4Biomarkers, TumorReceptors, CXCR4

Identifiers

PMID24714746
PMCPMC4007240

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.